All In Biotech

Drug Trial Radar · NCT04531982

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

454

Actual

Start

Aug 5, 2020

Primary completion

Jan 25, 2024

Study completion Feb 19, 2024

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Aug 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of negative symptoms of schizophrenia

Conditions

  • Schizophrenia

Interventions

  • PimavanserinDrug

    Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth

  • PlaceboDrug

    Placebo, taken as two blinded tablets once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26Time frame: 26 Weeks Treatment Duration

Locations

102 sites in 12 countries. Site status is shown where the registry gives one.

  • 603-Fundación para el Estudio y Tratamiento de las Enfermedades Mentales - FETEM

    Buenos Aires, Argentina

  • 610-Clinica Privada Banfield S.A.

    Buenos Aires, Argentina

  • 625-NOVAIN Neurociencias Group

    Buenos Aires, Argentina

  • 601-CENydET- Centro Neurobiologico y de Estres Traumatico-Biopsychomedical Research Group SRL

    Ciudad Autonoma Buenos Aires, Argentina

  • 602-FunDamoS

    Ciudad Autonoma Buenos Aires, Argentina

  • 622-Instituto Medico Damic Srl

    Córdoba, Argentina

  • 624-Centro Especializado en Neurociencias CEN

    Córdoba, Argentina

  • 626-Sanatorio Prof. Leon S. Morra S.A.

    Córdoba, Argentina

  • 617-INSA Instituto de Neurociencias San Agustin S.A.

    La Plata, Argentina

  • 623-Clinica Privada de Salud Mental Santa Teresa de Avila

    La Plata, Argentina

  • 607-Resolution Psicopharmacology Research Institute

    Mendoza, Argentina

  • 454-Mental Health Center Prof. Dr. Ivan Temkov - Burgas EO Burgas; Department for Treatment of Emergency Psychiatric Conditions

    Burgas, Bulgaria

  • 533-State Psychiatric Hospital - Kardzhali, EOOD

    Kardzhali, Bulgaria

  • 569-State Psychiatric Hospital - Lovech

    Lovech, Bulgaria

  • 535-UMHAT 'Dr. Georgi Stranski', EAD

    Pleven, Bulgaria

  • 586-Medical Center Mentalcare OOD

    Plovdiv, Bulgaria

  • 563-MC-Hipokrat-N E00D

    Plovdiv, Bulgaria

  • 592-Medical center Spectar - Plovdiv EOOD

    Plovdiv, Bulgaria

  • 570-Medical Centre "Sveti Naum"

    Sofia, Bulgaria

  • 526-DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan", OOD

    Sofia, Bulgaria

  • 405-"UMHAT Alexandrovska EAD, Sofia; Clinic of Psychiatry, First Department of Psychiatry "

    Sofia, Bulgaria

  • 568-Medical Center Hera EOOD

    Sofia, Bulgaria

  • 528-Medical Center Intermedica, OOD

    Sofia, Bulgaria

  • 590-State Psychiatric Hospital - Tzarev Brod

    Tsarev Brod, Bulgaria

  • 498-DCC "Mladost M" - Varna, OOD

    Varna, Bulgaria

  • 455-Mental Health Center - Veliko Tarnovo EOOD,

    Veliko Tarnovo, Bulgaria

  • 401-Mental Health Center - Vratsa EOOD, Vratsa; Department of Psychiatry

    Vratsa, Bulgaria

  • 532-MHAT "Dr. Hristo Stambolski", EOOD

    Kazanlak, Stara Zagora, Bulgaria

  • 536-Clinic for psychiatry Vrapce

    Zagreb, Croatia

  • 537-Clinic for psychiatry Vrapce

    Zagreb, Croatia

  • 550-Clinic for psychiatry Vrapce

    Zagreb, Croatia

  • 557-Clinic for psychiatry Vrapce

    Zagreb, Croatia

  • 594-klinika za psihijatriju Sveti Ivan, n/p Igor Filipčić or Marija Zelenika

    Zagreb, Croatia

  • 512-NeuropsychiatrieHK s.r.o.

    Hradec Králové, Czechia

  • 583-Narodni ustav dusevniho zdravi

    Klecany, Czechia

  • 519-A-SHINE s.r.o.

    Pilsen, Czechia

  • 513-CLINTRIAL s.r.o.

    Prague, Czechia

  • 499-MUDr. Tibor Miklos

    Prague, Czechia

  • 456-Semmelweis University Department of Psychiatry and Psychotherapy

    Budapest, Hungary

  • 520-Nyiro Gyula Korhaz - Orszagos Pszichiatriai es Addiktologiai Intezet

    Budapest, Hungary

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.